Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma

This retrospective study investigated the clinical efficacy and safety of bortezomib retreatment in patients with relapsed or refractory multiple myeloma (MM). A total of 30 patients who relapsed or progressed after ≥6 months since the last dose of their previous bortezomib therapy were included in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Jae-Sook, Jung, Sung-Hoon, Lee, Seung-Shin, Ahn, Seo-Yeon, Yang, Deok-Hwan, Kim, Yeo-Kyeoung, Kim, Hyeoung-Joon, Lee, Je-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233662/
https://www.ncbi.nlm.nih.gov/pubmed/25530955
http://dx.doi.org/10.1155/2014/145843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233662/
https://www.ncbi.nlm.nih.gov/pubmed/25530955
http://dx.doi.org/10.1155/2014/145843

Ejemplares similares